Drugs / Letrozole
Letrozole
also known as
femara · Letrozol · Femara (letrozole) · LET · Letrozole(Femara) · CGS 20267 · LTZ · Brand name Femar · +11 more
Other / unclassified targets CYP19A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | FEMARA | — | 2001-01-10 – 2010-04-30 | fda.gov ↗ |
| Approved | US (FDA) | FEMARA | — | 1997-07-25 | fda.gov ↗ |
Trials 458 · started per year
today
US approved 1997
1
2
1
5
2
6
10
11
17
10
12
21
10
13
6
15
13
12
22
30
23
21
29
27
23
32
25
22
20
17
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials · 1 met primary | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT05157672 | Dec 2021 → Aug 2023 | — | Washington State University | Unknown | No outcome recorded |
| Phase 0 | NCT04361175 | Mar → Sep 2021 | infertility disorder | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT04630210 | Feb 2021 → Jan 2025 | breast cancer | Universitaire Ziekenhuizen KU Leuven | Withdrawn | No outcome recorded |
| Phase 0 | NCT04130152 | Nov 2019 → Jan 2022 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 0 | NCT04049227 | Aug 2019 → Apr 2023 | endometrial endometrioid adenocarcinoma | Northwestern University | Completed | No outcome recorded |
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03122197 | May 2017 → Sep 2027 expected | brain neoplasm | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 0 | NCT02802748 | Jul 2016 → Jan 2018 | breast cancer | SOLTI Breast Cancer Research Group | Completed | Met primary |
| Phase 0 | NCT00651976 | Mar 2008 → Sep 2018 | breast cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 143 trials · 2 met primary · 1 missed | ||||||
| Phase 1 | NCT07867262 | Dec 2026 → Aug 2030 expected | breast cancer | Genentech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07401381 | Jun 2026 → May 2028 expected | hormone receptor-positive breast cancer | Rovi Pharmaceuticals Laboratories | Recruiting | No outcome recorded |
| Phase 1 | NCT07604571 | May 2026 → Jun 2032 expected | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06139107 | Aug 2024 → Sep 2026 overdue | breast cancer | Mridula George, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06813118 | Jun 2024 → Mar 2025 | polycystic ovary syndrome | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06253195 | Apr 2024 → Apr 2026 | hormone receptor-positive breast cancer, metastatic neoplasm | BeOne Medicines | Completed | No outcome recorded |
| Phase 1 | NCT06120283 | Dec 2023 → Dec 2029 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06315205 | Jul 2023 → Mar 2026 overdue | — | Rovi Pharmaceuticals Laboratories | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04316169 | Oct 2021 → Jan 2027 | female breast carcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04987632 | Aug 2021 → Dec 2022 | female infertility, polycystic ovary syndrome | Qiu-ping Lin | Unknown | No outcome recorded |
| Phase 1 | NCT05337657 | Jun 2021 → Dec 2023 | breast cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04177693 | Nov 2020 → Jan 2022 | leiomyoma | Yale University | Completed | Missed primary |
| Phase 1 | NCT03554044 | Feb 2020 → Dec 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06047184 | Jul 2019 → Oct 2023 | female breast carcinoma | BeBetter Med Inc | Unknown | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03401320 | Nov 2017 → May 2024 | — | Rovi Pharmaceuticals Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT03284723 | Nov 2017 → Aug 2021 | breast neoplasm | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT03308201 | Oct 2017 → Jun 2022 | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03128619 | Aug 2017 → Mar 2022 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma, progesterone-receptor positive breast cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02619669 | Apr 2017 → Jun 2019 | female breast carcinoma | Gary Schwartz | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02684032 | Jun 2016 → Jan 2022 | breast cancer | Celcuity Inc | Completed | No outcome recorded |
| Phase 1 | NCT02619162 | Jul 2015 → Nov 2017 | breast cancer | Spanish National Cancer Research Centre | Completed | Met primary |
| Phase 1 | NCT02448459 | May 2015 → Mar 2016 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT02333370 | Feb 2015 → Sep 2022 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02093351 | Sep 2014 → Apr 2015 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02152943 | Jul 2014 → Dec 2020 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02154776 | Jun 2014 → Oct 2016 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01870505 | May 2013 → Feb 2022 | female breast carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01791478 | Apr 2013 → Dec 2014 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive ductal breast carcinoma +1 | Vanderbilt-Ingram Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01693289 | Jan → Jun 2012 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT00945360 | Mar → May 2011 | uterine corpus leiomyoma | American University of Beirut Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01248494 | Nov 2010 → Dec 2012 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01208441 | Nov 2010 → Dec 2011 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01077453 | Mar 2010 → Jun 2014 | lobular breast carcinoma in situ | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1 | NCT01372982 | Apr → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01375452 | Mar → May 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT00648154 | Nov → Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648063 | Nov → Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00006174 | Aug 2000 → May 2009 | McCune-Albright syndrome, polyostotic fibrous dysplasia, precocious puberty | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 1/229 trials · 2 missed | ||||||
| Phase 1/2 | NCT07570966 | Jun 2026 → Aug 2031 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT07389733 | Mar 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07288359 | Dec 2025 → May 2031 expected | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06706414 | Mar 2025 → Aug 2026 overdue | male infertility | Martin Blomberg Jensen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05705505 | Mar 2023 → Jan 2026 | endometrial endometrioid adenocarcinoma | Traws Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05918718 | Jan 2023 → May 2024 | ectopic pregnancy | Tehran University of Medical Sciences | Unknown | Missed primary |
| Phase 1/2 | NCT05262400 | Mar 2022 → Feb 2027 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04486352 | Oct 2021 → Oct 2026 expected | endometrial cancer | Alliance Foundation Trials, LLC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04282031 | Jun 2020 → Dec 2024 overdue | hormone receptor-positive breast cancer | Beta Pharma (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03913234 | Jun 2019 → Oct 2023 | HER2 positive breast carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03772353 | May 2019 → Jun 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04488107 | Feb 2019 → Dec 2021 | breast neoplasm | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03709082 | Oct 2018 → Mar 2020 | HER2 positive breast carcinoma | University of Kansas Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03519178 | Mar 2018 → Apr 2023 | breast cancer | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03054363 | Nov 2017 → Jan 2023 | breast cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT02562118 | Oct 2015 → Jan 2027 expected | breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02520063 | Feb 2015 → Dec 2022 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT01686828 | Jun 2013 → May 2015 | hypogonadism, obesity disorder, type 2 diabetes mellitus | University of Washington | Completed | Missed primary |
| Phase 1/2 | NCT01484041 | Apr 2012 → Dec 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01105312 | Sep 2010 → Aug 2013 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00740194 | Aug → Dec 2008 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 1/2 | NCT00351416 | Jan 2004 → Jun 2009 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00290745 | Feb 2002 → Jul 2009 | breast cancer | University of California, San Francisco | Completed | Mixed |
| Phase 2197 trials · 11 met primary · 6 missed | ||||||
| Phase 2 | NCT07801898 | Sep 2026 → Sep 2028 expected | invasive breast carcinoma | The Second Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07826052 | Sep 2026 → Sep 2031 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07796880 | Sep 2026 → Sep 2028 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07795424 | Sep 2026 → Mar 2028 expected | HER2 positive breast carcinoma | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07866430 | Sep 2026 → Oct 2032 expected | estrogen-receptor positive breast cancer | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07394946 | Jun 2026 → Jul 2027 expected | hormone receptor-positive breast cancer | Cancer Care Hospital & Research Centre Foundation, Lahore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07483307 | Mar 2026 → Mar 2030 expected | Her2-receptor negative breast cancer, breast lobular carcinoma, estrogen-receptor positive breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07305246 | Dec 2025 → Mar 2027 expected | breast cancer | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Show all 197 trials opens the full record — a long page | ||||||
| Phase 2/317 trials | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07669402 | Dec 2023 → Feb 2026 | oligoasthenoteratozoospermia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT03458221 | Jan 2023 → Oct 2026 expected | ovarian cancer | Gynaecologisch Oncologisch Centrum Zuid | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05454358 | Aug 2022 → Dec 2025 | endometrial cancer | Fudan University | Terminated | No outcome recorded |
| Phase 2/3 | NCT05316935 | Jul 2022 → Mar 2028 expected | atypical endometrial hyperplasia, endometrium neoplasm, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06379113 | Jul 2022 → Mar 2028 expected | atypical endometrial hyperplasia, endometrium neoplasm, obesity disorder, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06390904 | Jul 2022 → Jul 2025 overdue | atypical endometrial hyperplasia, obesity disorder, progesterone resistance | Xiaojun Chen | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05203562 | Jun 2020 → Dec 2022 | gestational trophoblastic neoplasm | Zagazig University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03373708 | Dec 2017 → Dec 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT03507465 | Nov 2017 → Nov 2019 | breast cancer | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03285802 | Sep 2017 → Feb 2019 | uterine cancer | Greater Baltimore Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT05702957 | Sep 2016 → Oct 2019 | female infertility, polycystic ovary syndrome | Services Institute of Medical Sciences, Pakistan | Completed | No outcome recorded |
| Phase 2/3 | NCT02692755 | Sep 2016 → Dec 2019 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 2/3 | NCT02405156 | Mar 2015 → Dec 2016 | pregnancy disorder with abortive outcome | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02221999 | Sep 2013 → Jan 2019 overdue | breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00333047 | Jul 2002 → ? | breast cancer | Novartis | Completed | No outcome recorded |
| Phase 2/3 | NCT00535418 | Jun 2000 → Jul 2002 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 378 trials · 8 met primary · 7 missed | ||||||
| Phase 3 | NCT07340658 | Aug 2026 → Feb 2029 expected | breast cancer | Rovi Pharmaceuticals Laboratories | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07153757 | Sep 2025 → Sep 2033 expected | female breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06757634 | Jul 2025 → Mar 2029 expected | breast cancer | Celcuity Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06223698 | May 2025 → May 2032 expected | breast cancer | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06492616 | Sep 2024 → Aug 2029 expected | breast cancer | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 | Aug 2024 → Dec 2029 expected | breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06507618 | Jul 2024 → Jun 2029 expected | female breast carcinoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT06405243 | Jun → Dec 2024 | polycystic ovary syndrome | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT06418347 | Apr 2024 → Aug 2025 | female infertility, polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT06244745 | Dec 2023 → May 2025 overdue | ovarian cyst | IVI Madrid | Recruiting | No outcome recorded |
| Phase 3 | NCT06403488 | Oct 2023 → Jan 2024 | polycystic ovary syndrome | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT07616973 | May 2023 → May 2026 overdue | female infertility | Sana'a University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07143682 | Jan 2023 → May 2024 | female infertility, polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT05601700 | Sep 2022 → Sep 2029 expected | ovarian serous adenocarcinoma | Ente Ospedaliero Ospedali Galliera | Recruiting | No outcome recorded |
| Phase 3 | NCT05304273 | May 2022 → Jul 2024 | pregnancy disorder with abortive outcome | Calcutta National Medical College and Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06313983 | Jan 2022 → Dec 2025 overdue | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04341545 | Dec 2020 → Dec 2024 | tubal pregnancy | Queen Mary Hospital, Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT04111978 | Nov 2020 → Jul 2027 expected | fallopian tube neoplasm, malignant ovarian serous tumor, ovarian endometrioid adenocarcinoma, peritoneal neoplasm | Swiss GO Trial Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04421547 | Jun 2020 → Nov 2024 | malignant epithelial tumor of ovary | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Terminated | No outcome recorded |
| Phase 3 | NCT04158362 | Jun 2020 → Apr 2025 overdue | metastatic malignant neoplasm | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06486870 | Jan 2020 → Jan 2024 | polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04095364 | Sep 2019 → Feb 2027 expected | fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02912988 | Mar 2018 → Apr 2022 | infertility disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT03439046 | Feb 2018 → Dec 2023 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03664050 | Jan → Dec 2018 | ovarian hyperstimulation syndrome | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT03135301 | Jun 2017 → Dec 2023 | female infertility | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | Met primary |
| Phase 3 | NCT02941926 | Nov 2016 → Nov 2019 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03096847 | Oct 2016 → Dec 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03011684 | Jul 2016 → Mar 2028 expected | infertility disorder | University of California, San Francisco | Recruiting | Missed primary |
| Phase 3 | NCT02769104 | May 2016 → Jul 2018 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02600923 | Apr 2016 → May 2019 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02730091 | Feb 2016 → Mar 2020 | breast cancer | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded |
| Phase 3 | NCT03241472 | Feb 2016 → May 2017 | infertility disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02491320 | Aug 2015 → Oct 2019 | polycystic ovary syndrome | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| Phase 3 | NCT02900105 | Feb 2015 → Mar 2017 | azoospermia, oligospermia | KK Women's and Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02732808 | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT01950182 | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02918084 | Jun 2013 → Jun 2028 expected | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02980965 | May 2013 → Feb 2017 | female breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT01758146 | Jan 2012 → Jan 2020 | breast cancer | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT00908531 | May 2009 → Dec 2013 | female breast carcinoma | Danish Breast Cancer Cooperative Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00893061 | Mar 2009 → Apr 2012 | breast cancer | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 3 | NCT00949598 | Dec 2008 → Oct 2010 | breast cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 3 | NCT00601900 | Sep 2008 → Jun 2014 | invasive breast carcinoma | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 3 | NCT02338310 | Sep 2008 → Apr 2024 overdue | breast cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | Missed primary |
| Phase 3 | NCT00963729 | Sep 2008 → Mar 2010 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT01577017 | May 2008 → May 2009 | polycystic ovary syndrome | Nik Hazlina | Completed | No outcome recorded |
| Phase 3 | NCT00673335 | May 2008 → Jun 2019 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer, hereditary breast ovarian cancer syndrome | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00902954 | Mar 2008 → Jun 2010 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00545077 | Nov 2007 → Dec 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | Missed primary |
| Phase 3 | NCT00553410 | Aug 2007 → Apr 2018 | breast cancer | ETOP IBCSG Partners Foundation | Completed | Missed primary |
| Phase 3 | NCT00541086 | Mar 2007 → Jul 2020 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | Missed primary |
| Phase 3 | NCT00433589 | Feb 2007 → Mar 2020 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT00382070 | Aug 2006 → Aug 2016 | breast cancer | NSABP Foundation Inc | Unknown | Missed primary |
| Phase 3 | NCT00403182 | May 2006 → ? | female breast carcinoma | Technical University of Munich | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00332852 | Mar 2006 → Jul 2010 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00330317 | Feb 2006 → Mar 2010 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00265759 | Jan 2006 → Aug 2012 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00248170 | Dec 2005 → Sep 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00267553 | Nov 2005 → Jun 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00329940 | Nov 2005 → Jan 2008 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00138710 | Aug 2005 → Jan 2010 | hypogonadotropic hypogonadism, obesity disorder | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01064635 | Aug 2005 → Aug 2015 overdue | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | Met primary |
| Phase 3 | NCT00146146 | May 2005 → May 2006 | — | Unita Complessa di Ostetricia e Ginecologia | Completed | No outcome recorded |
| Phase 3 | NCT00171704 | Apr 2005 → Mar 2011 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00097344 | Dec 2004 → Aug 2006 | breast neoplasm | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT00610077 | Dec 2004 → Jul 2006 | infertility disorder | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00754845 | Nov 2004 → Dec 2015 | breast cancer | Canadian Cancer Trials Group | Completed | Met primary |
| Phase 3 | NCT00412022 | Mar 2004 → Nov 2024 | breast cancer | National Cancer Institute, Naples | Unknown | Met primary |
| Phase 3 | NCT00171314 | Mar 2004 → Nov 2010 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00171340 | May 2003 → Feb 2010 | breast cancer, disease of bone structure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00003140 | Aug 1998 → Aug 2003 | breast cancer | NCIC Clinical Trials Group | Completed | Met primary |
| Phase 3 | NCT00004205 | Mar 1998 → Dec 2008 | breast cancer | ETOP IBCSG Partners Foundation | Completed | Met primary |
| Phase 3 | NCT00001521 | Jun 1995 → Apr 2024 | congenital adrenal hyperplasia | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Missed primary |
| Phase 447 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT06985186 | Jun 2025 → Jun 2026 overdue | adenomyosis | University of Palermo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07160855 | May → Nov 2025 overdue | — | Nishtar Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06143631 | Jul 2024 → Sep 2028 expected | uterine corpus leiomyoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06354439 | Mar 2024 → Dec 2026 expected | tubal pregnancy | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| Phase 4 | NCT05168865 | Aug 2023 → Feb 2024 | polycystic ovary syndrome, pregnancy disorder with abortive outcome | Dubai Fertility Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04321551 | Jul 2023 → Jun 2028 | — | University of California, San Diego | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05341817 | Nov 2022 → Aug 2025 overdue | — | KK Women's and Children's Hospital | Recruiting | Missed primary |
| Phase 4 | NCT05362760 | Apr 2022 → Apr 2029 expected | hormone receptor-positive breast cancer | University of Ulm | Recruiting | No outcome recorded |
| Phase 4 | NCT05183828 | Jan 2022 → May 2026 | breast adenocarcinoma, female breast carcinoma, invasive breast carcinoma | University of Washington | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT04137640 | Jul 2021 → Nov 2025 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05198141 | Dec 2020 → Nov 2021 | ectopic pregnancy | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT04002635 | Dec 2020 → Apr 2021 | anovulation, female infertility, polycystic ovary syndrome | CRG UZ Brussel | Withdrawn | No outcome recorded |
| Phase 4 | NCT04590482 | Nov 2020 → Mar 2021 | pregnancy disorder with abortive outcome | Shereen Rady Abou El-fetouh | Unknown | No outcome recorded |
| Phase 4 | NCT05206448 | Oct 2020 → Apr 2024 overdue | infertility disorder, polycystic ovary syndrome | Rachel Mejia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04217265 | Jan → Apr 2020 | pregnancy disorder with abortive outcome | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04215835 | Jan → Apr 2020 | pregnancy disorder with abortive outcome | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04159649 | Dec 2019 → Dec 2020 | — | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03948568 | Sep 2019 → Jun 2021 | female breast carcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03901170 | Apr 2019 → Jun 2020 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04834791 | Mar → Oct 2019 | female infertility | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT04289805 | Feb 2019 → Jan 2025 | female breast carcinoma | Erasme University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03238703 | Sep 2018 → Mar 2023 | Her2-receptor negative breast cancer, breast carcinoma in situ, female breast carcinoma, invasive breast carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03111615 | May 2018 → May 2019 | female breast carcinoma | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 4 | NCT03355157 | Mar 2018 → Aug 2024 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02741154 | Aug 2016 → Aug 2017 | infertility disorder | Minia University | Completed | No outcome recorded |
| Phase 4 | NCT02802865 | Aug 2016 → May 2018 | infertility disorder, polycystic ovary syndrome | Rachel Mejia | Completed | Met primary |
| Phase 4 | NCT02703649 | Mar 2016 → Jul 2020 | anovulation | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 4 | NCT02470741 | Jul 2015 → Dec 2017 | leiomyoma | University of California, San Francisco | Completed | Missed primary |
| Phase 4 | NCT02288143 | Jan → Mar 2015 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01948804 | Jan → Mar 2014 | — | Pınar Özcan Cenksoy | Unknown | No outcome recorded |
| Phase 4 | NCT02097680 | Dec 2013 → Jun 2015 | obesity disorder | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02661932 | Nov 2012 → Mar 2018 | breast neoplasm, infertility disorder | Erasme University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02670304 | Jan 2012 → Jul 2013 | ovarian hyperstimulation syndrome | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT01553903 | Dec 2011 → May 2013 | breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01127295 | Jun 2010 → Dec 2017 | hormone receptor-positive breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01046578 | Jan 2010 → Feb 2012 | infertility disorder | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT01072318 | Jan 2010 → Jan 2014 | breast cancer | Korean Breast Cancer Study Group | Unknown | No outcome recorded |
| Phase 4 | NCT01908556 | Feb 2009 → Dec 2015 | — | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT00804960 | Sep 2008 → Dec 2009 | infertility disorder | Center for Human Reproduction | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00688909 | Mar 2008 → Jun 2009 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01315912 | Jan 2008 → Dec 2010 | female infertility | Bushehr University of Medical Science | Completed | No outcome recorded |
| Phase 4 | NCT01999569 | Apr 2007 → May 2008 | anovulation, ovarian cyst | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00237133 | Mar 2003 → Jan 2009 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00171847 | Mar 2003 → Oct 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00237224 | Feb 2003 → Feb 2007 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00241046 | Apr 2002 → Mar 2005 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00014638 | Jan 2001 → Mar 2002 | breast cancer | Novartis | Completed | No outcome recorded |
| Phase not applicable36 trials · 1 met primary | ||||||
| — | NCT07425990 | Mar 2026 → Feb 2027 expected | female infertility | University of Novi Sad | Recruiting | No outcome recorded |
| — | NCT07636317 | Jun 2025 → Mar 2026 | pregnancy disorder with abortive outcome | Sohag University | Completed | No outcome recorded |
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06605690 | Oct 2024 → Aug 2025 overdue | breast cancer | Liu Shu | Not yet recruiting | No outcome recorded |
| — | NCT06235931 | Feb 2024 → Dec 2025 overdue | breast neoplasm | Second Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06006091 | Aug 2023 → Aug 2026 overdue | female infertility | International Peace Maternity and Child Health Hospital | Recruiting | No outcome recorded |
| — | NCT05940233 | Jun 2023 → May 2025 overdue | — | Queen Savang Vadhana Memorial Hospital, Thailand | Recruiting | No outcome recorded |
| — | NCT05487092 | Dec 2022 → Dec 2026 expected | ovarian endometriosis | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT04169451 | Sep 2022 → Dec 2025 | infertility disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT06041204 | May 2021 → May 2026 overdue | female infertility, hypothyroidism, polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Recruiting | No outcome recorded |
| — | NCT05075863 | Jan → Jun 2021 | polycystic ovary syndrome | Nishtar Medical University | Completed | No outcome recorded |
| — | NCT04193930 | Jan 2021 | — | Assiut University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT04619914 | Mar → Jul 2019 | — | Laylay Mohammed Khalleefah Alhibshi | Completed | No outcome recorded |
| — | NCT03540979 | Jun 2018 → Dec 2019 | — | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT03455426 | Mar 2018 → Jun 2019 | infertility disorder | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT02775877 | May 2016 → Jun 2019 | female infertility | Navy General Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT03181919 | Jan 2016 → Jan 2017 | polycystic ovary syndrome | Benha University | Completed | No outcome recorded |
| — | NCT02647424 | Dec 2015 → Dec 2017 | infertility disorder, polycystic ovary syndrome | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02583828 | Jun 2015 → Dec 2020 | breast neoplasm, metastatic malignant neoplasm | Capital Medical University | Completed | No outcome recorded |
| — | NCT02377479 | Mar 2015 → Mar 2017 | infertility disorder | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT01793038 | Mar 2013 → Jun 2014 | infertility disorder, polycystic ovary syndrome | Mansoura Integrated Fertility Center | Unknown | No outcome recorded |
| — | NCT01720602 | Nov 2012 → Mar 2015 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT01669343 | Oct 2012 → Dec 2016 | breast neoplasm | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01780610 | Jan 2012 → Jan 2015 | infertility disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01475318 | Oct 2011 → Jun 2012 | — | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT01457703 | Jun 2010 → Jul 2013 | obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00997373 | Oct 2009 → Sep 2013 | endometrial carcinoma | University of California, Davis | Completed | Met primary |
| — | NCT01116167 | Oct 2009 → Dec 2013 | polycystic ovary syndrome | Heilongjiang University of Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01431352 | Sep 2009 → Aug 2014 | polycystic ovary syndrome | Heilongjiang University of Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01679574 | Jan 2009 → Jan 2012 | polycystic ovary syndrome | Assiut University | Completed | No outcome recorded |
| — | NCT00894608 | Jan 2008 → Dec 2009 | polycystic ovary syndrome | Yunyang Medical College | Unknown | No outcome recorded |
| — | NCT00565240 | Nov 2007 → Sep 2009 | — | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT01334762 | May 2007 → Jun 2010 | endometriosis | Mansoura University | Completed | No outcome recorded |
| — | NCT00956267 | Aug 2006 → Mar 2009 | polycystic ovary syndrome | Mansoura University | Completed | No outcome recorded |
| — | NCT00911313 | Jun 2006 → Jan 2009 | polycystic ovary syndrome | Mansoura University | Completed | No outcome recorded |
| — | NCT00114270 | May 2004 → Jun 2007 | breast cancer, osteoporosis | University of Virginia | Completed | No outcome recorded |
| Comparator or background therapy302 trials | ||||||
| Phase 0 | NCT05464810 Background | Sep 2022 → Apr 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT04088032 Background | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT03962647 Background | Jul 2019 → Mar 2024 | estrogen-receptor positive breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02538484 Comparator | Apr 2016 → Mar 2020 | breast cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT02341703 Comparator | Feb → Jul 2015 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Show all 302 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 38
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | AstraZeneca | Results Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 trial astrazeneca.com ↗
Median PFS2 was 25.7 months for the camizestrant combination compared with 19.1 months for the AI combination. |
| 2026-06-01 | BeOne Medicines | Results BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 beonemedicines.com ↗
The 240 mg dose of BGB-43395 plus letrozole resulted in a confirmed overall response rate (ORR) of 68.4% (95% CI: 43.4–87.4) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9). |
| 2026-05-22 | Oncolytics Biotech | Results Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors oncolyticsbiotech.com ↗
The combination of pelareorep, letrozole, and atezolizumab resulted in 60% of patients experiencing 30% or greater increases in their CelTIL score. |
| 2026-03-19 | Oncolytics Biotech | Results Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 oncolyticsbiotech.com ↗
The combination of pelareorep, letrozole, and atezolizumab resulted in 60% of patients experiencing 30% or greater increases in their CelTIL score. |
| 2026-03-09 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer roche.com ↗
The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. |
| 2026-03-08 | Genentech, Inc. | Results Genentech Provides Update on Phase III persevERA Study in ER-Positive Advanced Breast Cancer gene.com ↗
The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. |
| 2025-06-01 | AstraZeneca | Results Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗
Results showed the camizestrant combination reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI] 0.31–0.60; p<0.00001) as assessed by investigator. |
| 2025-02-26 | AstraZeneca | Results Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗ |
| 2023-12-05 | Eli Lilly and Company | Results Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium lilly.com ↗
For women with visceral organ metastases, data showed a median OS of more than five years, with an increase in median OS of 14.9 months in the Verzenio arm compared to the control arm (63.7 vs 48.8 months). |
| 2022-11-21 | Oncolytics Biotech | Results Oncolytics Biotech ® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗
Results published in the abstract showed that the studied combinations altered tumor microenvironments to induce and enhance anti-tumor immunity. |
| 2022-11-07 | Oncolytics Biotech | Results Oncolytics Biotech ® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights oncolyticsbiotech.com ↗
Flow cytometry analyses of blood samples from these patients showed a statistically significant increase in anti-cancer NK cells on day 21 post-treatment in cohort 2 compared to cohort 1. |
| 2022-06-04 | Pfizer | Results Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). |
| 2022-06-03 | Novartis Pharmaceuticals | Results New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer novartis.com ↗ |
| 2022-05-02 | Oncolytics Biotech | Results Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting oncolyticsbiotech.com ↗
Included in the abstract are new results from cohort 1 and cohort 2 of the AWARE-1 study, a collaboration between Oncolytics Biotech and SOLTI, each of which enrolled ten HR+/HER2- early-stage breast cancer patients. |
| 2022-03-10 | Novartis Pharmaceuticals | Results NEJM publication of Novartis Kisqali® data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer novartis.com ↗
Basel, March 9, 2022 — Novartis today announced that The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for Kisqali ® (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival. |
| 2021-12-10 | Novartis Pharmaceuticals | Results Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i novartis.com ↗
New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance |
| 2021-09-19 | Novartis Pharmaceuticals | Results Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer novartis.com ↗
Kisqali in combination with letrozole met its key secondary endpoint of OS, demonstrating a statistically significant and clinically meaningful improvement in survival (median 63.9 vs. 51.4 months; HR=0.76; 95% CI: 0.63-0.93; p=0.004) 2 . |
| 2021-03-25 | Pfizer | Results Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗
Median OS was not reached among patients in the IBRANCE group and was 43.1 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 to 0.82; P=0.0002). |
| 2020-09-21 | Novartis Pharmaceuticals | Results Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale novartis.com ↗
A trend toward improved progression free survival (PFS) for Kisqali plus fulvestrant versus palbociclib plus letrozole was also observed. |
| 2020-05-27 | Novartis Pharmaceuticals | Results Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease novartis.com ↗
Results were consistent with those observed in the MONALEESA trials, including median time to progression 27.1 months (95% CI: 25.7-NE) and overall response rate 43.6% (95% CI: 41.5-45.8%). |
| 2019-09-24 | Pfizer | Results Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019 pfizer.com ↗
In this retrospective analysis ( Abstract #329P: Comparative effectiveness of palbociclib plus letrozole vs. letrozole for metastatic breast cancer in U.S. real-world clinical practices) , treatment with IBRANCE plus letrozole demonstrated a statistically significant improvement in real-world progression-free survival (rwPFS) compared to letrozole alone: 24.5 months (95% CI = 20.7 – 32.7) versus 17.1 months (95% CI = 13.7 – 19.8) (HR = 0.68, 95% CI = 0.56 – 0.84, p = 0.0003). |
| 2017-12-06 | Pfizer | Results Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® (palbociclib) combined with letrozole. |
| 2017-10-06 | Eli Lilly and Company | Results Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer lilly.com ↗
MONARCH 3 met a rigorous threshold for demonstrating efficacy at the time of pre-planned interim analysis with a 46 percent reduction in the risk of progression or death in patients receiving initial therapy for metastatic disease. |
| 2017-08-24 | Novartis Pharmaceuticals | Regulatory Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗ |
| 2017-06-23 | Novartis Pharmaceuticals | Regulatory Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗
The CHMP recommendation of combining Kisqali with any aromatase inhibitor means that, if approved, oncologists could prescribe Kisqali with letrozole, anastrozole or exemestane, giving them the discretion to select the therapy they believe is most appropriate for each individual patient. |
| 2017-06-02 | Novartis Pharmaceuticals | Results Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer novartis.com ↗
After an additional 11 months of follow-up, a median progression-free survival (PFS) of 25.3 months (95% CI: 23.0-30.3) for Kisqali plus letrozole and 16.0 months (95% CI: 13.4-18.2) for letrozole alone was observed (HR=0.568 (95% CI: 0.457-0.704; p<0.0001))[1]. |
| 2017-04-24 | Eli Lilly and Company | Results Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis lilly.com ↗
INDIANAPOLIS, April 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS). |
| 2016-12-21 | Pfizer | Regulatory FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗
The sNDA supports the conversion of the accelerated approval of IBRANCE in combination with letrozole to regular approval and includes data from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE as initial therapy in combination with letrozole for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. |
| 2016-12-19 | Pfizer | Results Pfizer Presents Data from PALOMA-2 Phase 3 Study Demonstrating Clinical Benefit of IBRANCE® (palbociclib) in Asian Women with ER+, HER2- Metastatic Breast Cancer at ESMO Asia Congress pfizer.com ↗
Results showed the combination of IBRANCE and letrozole significantly extended progression-free survival (PFS) by more than 11 months compared with letrozole plus placebo, and demonstrated that the median PFS exceeded two years in these patients. |
| 2016-12-09 | Novartis Pharmaceuticals | Results Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole novartis.com ↗
These findings demonstrate the strength of LEE011 plus letrozole in the first-line setting, showing that treatment benefit was evident across all patient subgroups regardless of their disease burden or tumor location, including those patients with aggressive disease. |
| 2016-11-16 | Pfizer | Results PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer pfizer.com ↗
The PALOMA-2 study showed the combination of IBRANCE and letrozole extended progression-free survival (PFS), or the amount of time before tumor growth, by more than 10 months compared with letrozole plus placebo. |
| 2016-11-01 | Novartis Pharmaceuticals | Regulatory Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer novartis.com ↗
A marketing authorization application for LEE011 plus letrozole has also been accepted for review by the European Medicines Agency (EMA) |
| 2016-10-08 | Novartis Pharmaceuticals | Results Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care novartis.com ↗
LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups |
| 2016-05-18 | Novartis Pharmaceuticals | Results MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer novartis.com ↗
LEE011 (ribociclib), a CDK4/6 inhibitor, in combination with letrozole, showed clinically meaningful improvement in PFS in postmenopausal women who had received no prior therapy for advanced breast cancer[1] |
| 2016-04-19 | Pfizer | Results Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib) pfizer.com ↗
The study met its primary endpoint by demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo in post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer who had not received previous systemic treatment for their advanced disease. |
| 2014-10-29 | Lannett Company, Inc. | Regulatory LANNETT RECEIVES FDA APPROVAL FOR LETROZOLE TABLETS USP 2.5 MGPDF Version investorroom.com ↗ |
| 2010-01-28 | GlaxoSmithKline | Regulatory GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer gsk.com ↗
Lapatinib is now indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. |
| 2010-01-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Generic Femara® Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. |
All press releases naming this drug 40 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 767 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Letrozole | “POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO...” PMID 33152284 ↗ Nov 2020755“One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor-positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for...” PMID 16877730 ↗ Aug 2006 “Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗ “The experimental arm receives ribociclib at the standard dose (orally, 400mg, once daily on days 1-21 of a 28-day cycle) combined with a specified endocrine therapy (e.g.,...” NCT07380646 ↗ “aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1...” NCT01220128 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones...” NCT03959891 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Letrozole：2.5mg，q4w or Anastrozole：1mg，q4w or Exemestane：25mg，q4w or Fulvestrant:Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then...” NCT07810088 ↗ |
| Known as | Brand name Femar | “Brand name Femar” NCT01615211 ↗ |
| Known as | CGS 20267 | “Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor.” NCT06367712 ↗1“Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor.” NCT04619914 ↗ |
| Known as | femar | “24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo.” NCT05205837 ↗ |
| Known as | Femar, letrozol, Novartis Healthcare | “Femar®, letrozol, Novartis Healthcare” NCT00935558 ↗ |
| Known as | femara | “The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene...” NCT00044291 ↗38“Based on the results from this trial, the aromatase inhibitor letrozole (Femara) is currently recommended as a part of standard adjuvant therapy for postmenopausal women with...” PMID 17912636 ↗ Oct 2007 “In the letrozole group, withdrawal bleeding was achieved using 10 mg of dydrogesterone tablets for 10 days before stimulation, then 2.5 mg of letrozole oral tablets (Femara;...” NCT00956267 ↗ “The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal...” NCT00461773 ↗ “The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®)...” NCT00134680 ↗ “letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated...” NCT05166668 ↗ “Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a...” NCT04047758 ↗ “Group 2 will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.” NCT02304107 ↗ “Group 1 will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding” NCT02305693 ↗ “Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor which is used in the treatment of hormonally-responsive breast cancer after surgery.” NCT03901170 ↗ “This is a randomized phase II study of letrozole (Femara) administered 2.5 mg orally daily to patients with newly diagnosed clinical stage I and II LMS.” NCT05649956 ↗ |
| Known as | Femara (letrozole) | “Femara (letrozole)” NCT01897441 ↗3“Femara (letrozole)” NCT00240071 ↗ “Femara (Letrozole)” NCT00530868 ↗ “Femara (Letrozole)” NCT01248416 ↗ |
| Known as | FemarTM | “Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months.” NCT05163106 ↗ |
| Known as | Fermara | “Fermara® (letrozole) 2.5 mg/day PO” NCT00828854 ↗ |
| Known as | LEBE | “single IM injection of Letrozole LEBE 75 mg” NCT06315205 ↗ |
| Known as | LET | “The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with...” PMID 29404806 ↗ Feb 20183“The National Cancer Institute of Canada Clinical Trials Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in...” PMID 18332475 ↗ Mar 2008 “After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are...” NCT04321551 ↗ “In Phase 2, the same protocol was employed with the addition of an aromatase inhibitor (letrozole, LET) administered daily beginning at week 4 for 2 weeks.” PMID 28187771 ↗ Feb 2017 |
| Known as | Letrofem | “Clomiphene citrate (Ovumid®, Iran Hormones Company) 25 mg/day with co-treatment of Letrozole (Letrofem®, Iran Hormones Company) 2.5 mg/day are given from cycle day 3 onwards.” NCT02732808 ↗ |
| Known as | letrol | “The experimental arm (p1) will be treated with letrozole 5 mg for 10 days. The comparator arm (p2) will receive letrozole 10mg for 5 days (Tab letrol 2.5mg -Renata Pharmaceutical.” NCT07448272 ↗ |
| Known as | Letrozol | “The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).” NCT06120595 ↗5“Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.” NCT03111615 ↗ “4. Letrozol tablets, 2.5 mg x 1 orally” NCT03378297 ↗ “Letrozol or Anastrozol or Exemestane” NCT02592083 ↗ “Femar®,letrozol, Novartis Healthcare” NCT00935558 ↗ |
| Known as | Letrozole component of kisqali femara co-pack | ChEMBL registry synonym — accepted as the source's own label CHEMBL1444 ↗ |
| Known as | Letrozole Tablets | “Drug: Letrozole Tablets” NCT04906395 ↗ |
| Known as | Letrozole(Femara) | “Letrozole (Femara)” NCT06218303 ↗ |
| Known as | Letrozole(Femara, Novartis Pharmaceuticals) | “Letrozole(Femara, Novartis Pharmaceuticals)” NCT02491320 ↗ |
| Known as | LTZ | “Postmenopausal women with untreated stage I-III HR+/HER2-negative breast cancer were randomized (1:1:1) to receive 3 weeks of letrozole (LTZ) 2.5 mg/day, oral mVNB 50 mg 3...” PMID 31533777 ↗ Sep 20191“The use of aromatase inhibitor, letrozole (LTZ), in reproductive medicine started in 2001.” NCT02647424 ↗ |
| Known as | NSC-759652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1444 ↗ |
| Action | Inhibit | “Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.” NCT00001521 ↗ |
| Modality | Other / unclassified | “the aromatase inhibitor letrozole” PMID 16145047 ↗ Sep 2005 |
| Route | Oral | “letrozole - 1.5mg/m\^2 body surface area orally” NCT00001521 ↗ |
| Target | CYP19 | “Letrozole is a potent and highly selective third generation aromatase inhibitor that was developed in the early 1990's. Aromatase is an enzyme of the cytochrome P-450...” NCT01035099 ↗ |